Overview
Synoptis Pharma is an experienced Polish manufacturer of prescription and over-the-counter medicines, food supplements, medical devices and dermocosmetics. The company draws on the NEUCA Group’s 30 years of experience and offers a broad product portfolio, competitive prices and resale support.
Financials
Revenue history (in m)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2005-01-17. Active
37 1160 2202 0000 0001 1318 2648- 50 1160 2202 0000 0001 6508 4398
- 66 1160 2202 0000 0002 3652 1506
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
No public aid cases recorded in the last 10 years.
Tenders
No recorded participation in tenders.
Trademarks
Synoptis Pharma holds 193 active trademarks registered with the Polish Patent Office. 11 applications are pending. 46 marks have expired or were not registered. The first mark was filed in 2009.
| Mark | Protected until | |
|---|---|---|
| Dapheria(word) | Jan 30, 2036 | |
| HONEY TUSS(word) | Jan 30, 2036 | |
| BUPROXIL(word) | Jan 15, 2036 | |
| LISDAVEX(word) | Jan 15, 2036 | |
| TRAZOXIN(word) | Jan 15, 2036 |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 KNF | Consumer credit intermediary | Active | |
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
The making of declarations on behalf of the company requires the joint action of two members of the management board, or of one member of the management board jointly with a commercial proxy.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Neuca S.A. | 360,000 | $4,862,236.63 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Subsidiaries
| Name | Share value | Stake | ||
|---|---|---|---|---|
Synoptis Industrialsp. z o.o. | 4,402,957.86 USD | 99.9985% |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Anpharm Przedsiębiorstwo FarmaceutyczneS.A. | $111,469,394.21 | anpharm.pl | ||
| Tarchomińskie Zakłady Farmaceutyczne PolfaS.A. | $102,988,448.02 | polfa-tarchomin.com.pl | ||
| VercoS.A. | $43,577,172.02 | verco.com.pl | ||
| MedicofarmaS.A. | $8,530,473.72 | medicofarma.pl | ||
| VitamaS.A. | $4,287,087.38 | vitama.pl | ||
| Munar PharmaS.A. | $85,649.72 | munar.pl | ||
| Sanford Biotechsp. z o.o. | $2,586.64 | sanfordbiotech.com | ||
| Cefeasp. z o.o. | $294.66 | cefea.pl | ||
| Auxilius PharmaS.A. | $0.83 | auxiliuspharma.com | ||
| Stg25Branch (foreign co.) | – | glagolica.eu |
Change history
| Date | Event | |
|---|---|---|
| 2015-07-02 | PKD change (Removed: 17.22.Z, 17.23.Z, 20.42.Z, 20.53.Z, 45.11.Z, 45.19.Z, 46.39.Z, 46.65.Z, 46.66.Z, 46.69.Z, 46.71.Z, 46.90.Z, 47.29.Z, 47.74.Z, 47.78.Z, 49.39.Z, 49.41.Z, 52.10.B, 53.20.Z, 58.13.Z, 58.14.Z, 58.19.Z, 58.29.Z, 62.01.Z, 62.02.Z, 63.11.Z, 63.12.Z, 64.99.Z, 66.19.Z, 66.22.Z, 68.10.Z, 68.20.Z, 68.32.Z, 69.20.Z, 70.21.Z, 70.22.Z, 73.11.Z, 73.12.A, 73.12.B, 73.12.C, 73.12.D, 73.20.Z, 74.90.Z, 77.12.Z, 77.33.Z, 78.10.Z, 78.20.Z, 78.30.Z, 79.11.A, 79.11.B, 79.12.Z, 82.20.Z, 82.30.Z, 82.92.Z, 85.59.B, 86.10.Z, 86.90.D; Added: 46.74.Z) | |
| 2012-10-23 | Address change (Taśmowa 7, 02-677, Warszawa → Krakowiaków 65, 02-255, Warszawa) | |
| 2010-11-30 | Address change (Aleje Jerozolimskie 151, 02-326, Warszawa → Taśmowa 7, 02-677, Warszawa) | |
| 2010-11-30 | Share capital change (14,000,000.00 PLN → 18,000,000.00 PLN) | |
| 2010-02-16 | Share capital change (55,000.00 PLN → 14,000,000.00 PLN) |
FAQ
Last updated: 2026-10-07